Clinical Trial Update: Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity [Phase 4]

View source ↗

Summary

Phase 4 trial investigating the effects of IL-23 inhibition by risankizumab on psoriasis autoimmunity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Psoriasis | Phase 4 | Status: UNKNOWN